IVI Middle East is a unique asset operated by a distinguished management team and is rightly positioned to continue on its journey of extraordinary growth.” We engaged with the management team at IVI Middle East well ahead of the sale process which allowed us a in depth understanding of business and the IVF opportunity in the Gulf region. Gaurav Marathe, head Lincoln’s Healthcare Group in India and CEO India, commented, “We are delighted to have advised the shareholders of IVI Middle East on the sale to Gulf Capital.
With Gulf Capital’s support, we want to continue deepening our presence in the Gulf region and to grow this into a global platform.” Suresh Soni, CEO of IVI Middle East, commented on the transaction, “In Gulf Capital we have found a highly reputable and financially-strong partner to help us realize the further development of our company. The company’s embryologists working in these laboratories are extensively trained, providing them exposure to global best practices in IVF. IVI-RMA Global is committed to providing fertility solutions to offer the best chance of success in the shortest time possible and with their upcoming expansion projects in New Jersey and. IVI Middle East has an exceptional infrastructure backed by ESHRE trained doctors. The research-driven approach to treatment methodology drives the higher success rates. IVI Middle East offers personalized treatment and advanced treatment methodologies in IVF. Since its formation, IVI Middle East has delivered significantly better medical outcomes whilst ensuring the safety of patients coupled with the highest ethical standards. The company is positioned to continue to deliver accelerated growth in a market that is growing at 10%+ every year. IVI, is a leading reproduction medicine centre, offering the best fertility treatments and techniques in Spain, both to Spaniards as to foreign patients.
IVI Middle East is the largest global player in the Gulf region offering world-class facilities and clinical protocols comparable to the highest global success rates.
#IVI RMA GLOBAL FULL#
The company has two full-service clinics in Abu Dhabi and Muscat along with one outpatient clinic in the Dubai. LeadCandy provides Full Profile, verified Email Address, Social Profile links, and Mutual Contacts of IVI RMA GLOBAL employees. All rights reserved.Back to Transactions IVI RMA Global and other shareholders have sold their stake in IVI Middle East to Gulf Capitalįounded in 2015 by IVI (now IVIRMA), Suresh Soni, Dr Human Fatemi, IVI Middle East emerged as the leading IVF provider in the Middle East market. Turner Syndrome mosaic Turner oocyte donation preimplantational genetic diagnosis.Ĭopyright © 2020 American Society for Reproductive Medicine. Nevertheless, PGT-A is a valid therapeutic option in patients with MTS using their own oocytes, and OD should not necessarily be directly recommended. Oocyte donation is the best reproductive option in females with Turner Syndrome with or without mosaicisms. While focusing on the X chromosome, partial MTS (PTS), we found significant differences in the CLBR per embryo transfer, with 77.6% vs. Likewise, the LBR per patient was significant when comparing PGT-A vs. The live birth rate (LBR) per embryo transfer in patients with MTS tended to be higher in OD 37.7% (95% confidence interval : 29.3-46.1) than that observed for PGT-A 22.5% (95% CI 7.8-38.2), and the cumulative LBR (CLBR), with 77.6% vs. Reproductive outcome and feto-maternal outcomes. In vitro fertilization for PGT-A (fluorescence in situ hybridization/arrays-next generation sequencing) or OD. Segnala profilo Informazioni Hi, Everyone I am Maria Getuli, an analytical and detail-oriented executive with extensive experience overseeing day-to-day business operations with analysis of ongoing performance and statistics to achieve competent operational accomplishments, including market. The study included 90 women with MTS and 20 women with pure Turner Syndrome (PTS) who underwent 140 and 25 oocyte donation (OD) cycles, respectively. University-affiliated private in vitro fertilization center.įifty-six patients with MTS with whom 65 ovarian stimulation cycles for PGT-A (fluorescence in situ hybridization/arrays-next generation sequencing) were performed. Retrospective observational multicenter study. The impact of the assisted reproduction technique (ART) performed (PGT-A or oocyte donation) and the type of absence of the X chromosome (total or partial) were considered. To describe the outcome of preimplantation genetic testing (PGT-A) using their own oocytes in patients with mosaic Turner Syndrome (MTS).
0 kommentar(er)
